Provider’s Corner
This Providers’ Corner contains resources that licensed healthcare professionals may find useful regarding Humavir.
Presentations
Documents
Research
Management of Chronic EBV Infection
Learn an evidence-based method to resolve chronic active Epstein Barr viral infections with case examples. This presentation also includes supplemental material specific to SARS-CoV-2 and CMV.
This presentation has been designed to support for self-study.
For those interested in additional background on the pathophysiology of Epstein Barr, Cytomegalo, and HHV-6 viral infections, please send an email to contact@humeo.io and request the October 2023 AMMG presentation by Dr. Bump.
Review of Research & Clinical Milestones – Humavir
The presentation consolidates initial research in humic acid with the clinical development of Humavir, including clinical trial results. Updated data on heavy metals is included as is a synopsis of data regarding mineral status (Mg, Zn, Ca, Fe) on Humavir use greater than 6 months.
This presentation was originally shared at the Age Management Medicine Conference in April 2022.
To access this presentation, please inquire directly at contact@humeo.io.
2023 COVID Update: Through the Lense of Functional Medicine
This presentation provides up to date insight on a functional approach to Covid-19 through an expanded genomic lens with prophylactic and treatment protocols.
The Genomics of a Pandemic: Human Polymorphisms, Viral Sabotage, and Functional Medicine Solutions
This presentation sifts through genomic polymorphisms that contribute to viral susceptibility and then presents natural solutions using a case study model.
Humavir is built around an enhanced version of the “Humic Acid 95%”
referenced in the presentation.
Prophylaxis: The Vaccines & Humic Acid, COVID and the Changing World, June 2021
To access this presentation, please inquire directly at contact@humeo.io.
Advanced Topics in Clinical Humeomics
Temporarily Unavailable: This 26-minute presentation provides the listener with insight into the considerations that guided the development of Humavir while answering relevant clinical questions.
Enhancing a Natural Viral Fusion Protein Inhibitor
Temporarily Unavailable: This nearly 10-minute presentation introduces the listener to the bench science that prompted the development of HumavirMD.
Healthcare Provider FAQ
This referenced FAQ supplements a healthcare provider’s fund-of-knowledge regarding clinical humeomics and Humavir.
Product Reference Sheet – Humavir
This product reference sheet is a comprehensive reference for physicians and their patients which includes data from the human clinical studies completed with humic acid and Humavir.
Product Reference Sheet – Humavir, abridged
This simplified face sheet removes the human clinical trial data presented in the comprehensive product reference sheet as well as storage instructions.
Product Reference Sheet Bibliography – Humavir
This bibliography references peer-reviewed literature that is relevant to Humavir’s regard as an immune support product.
Primary Anti-Viral Mechanism
Primary mechanism of action
Unpublished in vitro studies performed in the late 1990s revealed that an iteration of humic acid exhibited both prophylactic and therapeutic anti-viral effects against HIV in cell culture.
It is now understood that purified humic acid binds onto the receptor binding domain, or spike protein, of enveloped viruses and encapsulates them in a water-based gel, or hydrogel. This binding phenomenon inhibits viral binding to its target cell membrane receptors.
Tumor necrosis factor alpha
Tumor necrosis factor alpha (TNF-α) is a protein made by activated immune cells. At moderate concentrations, it promotes the fever response and the elevation of other pro-inflammatory proteins, which together contribute to symptoms that are typical of an inflammatory response to infectious disease.
Blood samples of study participants revealed a greater decrease in TNF-⍺ concentrations in study participants using HumavirMD than humic acid alone.
Immunomodulation
Humic acids have been shown to stimulate the immune system in prior studies.
One marker of immune system integrity, the T-helper cell, or CD4+ cell, was followed during human clinical studies with humic acid and then Humavir.
Blood samples of study participants revealed a greater increase in CD4+ count in study participants using Humavir versus humic acid alone.
Accelerated clinical outcomes
The visual analogue scale is a validated psychometric response scale that is often used to assess subjective characteristics or impressions that cannot be directly measured quantitatively.
The human clinical studies performed with humic acid and Humavir yielded improved outcomes versus placebo. Participants in the Humavir study expressed a greater sense of wellness and readiness to return to activities of daily living, including work, than those using humic acid alone. Both test groups had higher wellness ratings than their placebo groups.
